The prognostic value of changes in the plasma cytokine profile of neuroresuscitation patients with ventilator-associated pneumonia: two center observational study

E.P. Zinina, S.V. Tsarenko, D.Y. Logunov, A.I. Tukhvatulin, M.A. Magomedov, A.V. Babayants

1 Federal Center of Treatment and Rehabilitation, Moscow, Russia
2 City Clinical Hospital No 52, Moscow, Russia
3 N.F. Gamaleya Institute of Epidemiology and Microbiology, Moscow, Russia
4 Pirogov City Clinical Hospital, Moscow, Russia
5 Pirogov Russian National Research Medical University, Moscow, Russia
6 S.S. Yudin City Clinical Hospital, Moscow, Russia
7 Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitiology, Moscow, Russia

Abstract

Objectives. This study was performed to find changes in the plasma cytokine profile of neuroresuscitation patients with ventilator-associated pneumonia, and to search for prognostic markers of effectiveness of antibacterial treatment of ventilator-associated pneumonia. Materials and methods. A two-center clinical study, that included 73 patients aged 19 to 82 years with neurosurgical and neurological pathology and signs of ventilator-associated pneumonia (VAP) was conducted. On the 1st and 3rd days of antibiotic therapy, plasma samples were taken from patients, in which the concentration of 59 cytokines was determined. Retrospectively, patients were divided into groups of favorable and unfavorable clinical course of VAP. Predictors of the clinical course of the disease were identified using statistical methods, ROC analysis, and logistic regression. Results. Matrix metalloproteinase-2 (MMP-2) was the most sensitive predictor of the clinical outcomes of VAP in neuroresuscitation patients. In the group of patients with an unfavorable course of VAP, the concentration of MMP-2 in plasma was initially increased, but significantly decreased by the 3rd day, in contrast to the group with good outcomes.
The logistic regression model predicted the clinical course of VAP with an accuracy of 69.2 %. Less sensitive but significant predictors of the clinical course of the disease were cytokines: interleukin-1 receptor antagonist, interleukin-6, granulocyte colony-stimulating factor, tumor necrosis factor superfamily member 14, osteocalcin, pentraxin, thymic stromal lymphopoietin, element 12 of the tumour necrosis factor ligand superfamily, and interleukin-12. **Conclusions.** Measurement of plasma cytokine levels is a prospective method to determine the effectiveness of antibacterial therapy in VAP. Matrix metalloproteinase-2 is a sensitive predictor of the clinical course of VAP in neuroresuscitation patients.

**Keywords:** nosocomial pneumonia, ventilator-associated pneumonia, cytokines, matrix metalloproteinase-2

"For correspondence": Elizaveta P. Zinina — MD, anesthesiology and intensive care specialist, Anesthesiology and intensive care unit #1, Federal Center of Treatment and Rehabilitation, Moscow, Russia; e-mail: epzinina@gmail.com

"For citation": Zinina E.P., Tsarenko S.V., Logunov D.Y., Tukhvatulin A.I., Magomedov M.A., Babayants A.V., Avramov A.A. The prognostic value of changes in the plasma cytokine profile of neuroresuscitation patients with ventilator-associated pneumonia: two center observational study. Annals of Critical Care. 2021;4:48–58. DOI: 10.21320/1818-474X-2021-4-48-58

**Received**: 23.08.2021
**Accepted**: 30.11.2021
**Published online**: 19.01.2022
Introduction

Nosocomial pneumonia (NP) is the most common infectious complication in the intensive care unit (ICU) [1]. NP accounts for 25% of all infectious complications in the ICU, and more than half of all prescribed antibiotics are used for its treatment [2]. The frequency of ventilator-associated pneumonia (VAP) reaches 86% of all cases of postoperative pneumonia in surgical patients [3]. Delay of diagnosis and administration of the correct starting antimicrobial therapy for VAP significantly increases the duration of hospital stay and mortality [4]. According to some data, the incidence of VAP in neurosurgical patients reaches 40-50% [5]. Neurosurgical and neurological patients often require prolonged mechanical ventilation (MV), and, therefore, the problem of respiratory complications is especially relevant among such patients [6]. Usually, patients undergoing elective neurosurgical interventions, as well as patients with acute cerebrovascular accidents (ACVA), do not exhibit signs of respiratory infection before the transfer to mechanical ventilation. The development of VAP, therefore, is a consequence of mechanical ventilation, while the transfer to MV requires readiness to treat associated infections [7].

The emergence of an infectious process in the lungs during hospitalization should be considered as a result of an imbalance between the factors of anti-infection protection and factors associated with the underlying disease and its treatment, contributing to the entry of potentially pathogenic microorganisms into the respiratory tract. Thus, the development of nosocomial pneumonia is associated with pathogenic microflora overcoming the antimicrobial defense mechanisms. The state of the immune response can be assessed by the change in the concentration of cytokines released at different stages of pneumonia [8].

According to the European guidelines for the treatment of NP and VAP, published in 2017, biomarkers that can be used to assess the course of pneumonia include C-reactive protein (CRP), procalcitonin, copeptin (a protein fragment of the prohormone vasopressin), and the mid-regional proatrial natriuretic peptide (MP-proANP). At the same time, research results indicate the low specificity and predictive value of these markers. In this regard, it is not recommended to routinely measure biomarkers to predict the outcome of the disease or the effectiveness of therapy on the 3-4 day of VAP [9]. In addition, the correlation between concentrations of known mediators of inflammation, markers of endotoxosis, or specific biomarkers can significantly vary at the serum, tissue and cell levels [27]. Despite this, many studies indicate that cytokines may be promising as predictors of the severity of both community and nosocomial pneumonia [28].

Considering the above, the identification of potential biomarkers of effectiveness of antibiotic therapy in VAP is a relevant task.

Purpose of the study: to investigate changes the plasma cytokine profile in neuroresuscitation patients with VAP and to determine potential markers of antibiotic therapy effectiveness.

Materials and methods

Our two-center observational study was conducted at the Federal Center of Treatment and Rehabilitation and the Pirogov City Clinical Hospital in Moscow, Russia. The study of biological material was carried out at the N.F. Gamaleya Institute of Epidemiology and Microbiology, Moscow, Russia. 73 patients were included in the study (40 men and 33 women), from 19 to 82 years of age, according to the inclusion and exclusion criteria.

Inclusion and exclusion criteria

The inclusion criteria were:
1) Patients 18 to 85 years of age
2) MV for more than three days
3) Signs of VAP according to clinical and radiological data (computed tomography): more than 5 points on the Clinical Pulmonary Infection Score (CPIS) [26].
4) The presence of brain damage or diseases of the central nervous system, including those requiring surgery.

The exclusion criteria from the study were:
1) The presence of an extrapulmonary infectious process (peritonitis, meningitis).
2) The presence of isolated tracheobronchitis (without signs of infiltration of lung tissue according to computed tomography)
3) Weaning from mechanical ventilation during the observation period (1-3 days from the start of antibiotic therapy).

Study design

The observation period for each patient was 5 days. The first day of the study was the day of antibiotic administration when signs of VAP were detected. On days 1 and 3, all patients underwent blood sampling to determine the concentration of cytokines, the levels of leukocytes, CRP, and body temperature. On the first day, the blood samples were taken before the administration of antibacterial drugs. Plasma obtained after centrifugation of blood samples was placed in tubes with protease inhibitors (SIGMAFAST ™ Protease Inhibitor Tablets, Category No. S8820, containing 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride,
Principles of intensive care

All patients included in the study received antibiotic therapy in accordance with the sensitivity of local nosocomial flora of the intensive care unit. Respiratory support was carried out within the concept of protective ventilation: pressure-controlled ventilation modes, tidal volume - 6-8 ml/kg, positive end-expiratory pressure - 8-12 cm H₂O.

Investigation of the differences in the hospital microbiological landscape, as well as the range of prescribed antibiotics was not included in the objectives of this study. In addition, the study did not take into account the differences in treatment tactics of underlying diseases, fluid resuscitation and enteral nutrition between the groups.

Patient group stratification

Retrospectively, patients were divided into two groups (conventionally designated as “white” and “red”) depending on the clinical course of the disease. The “white” group included patients, whose condition improved after starting antibiotic therapy or replacing antibiotic therapy during the study period (successful antibiotic therapy, N = 36).

The “red” group included patients whose condition did not change or worsened, despite the ongoing antimicrobial therapy in accordance with the sensitivity of local nosocomial flora of the intensive care unit. Respiratory support was carried out within the concept of protective ventilation: pressure-controlled ventilation modes, tidal volume - 6-8 ml/kg, positive end-expiratory pressure - 8-12 cm H₂O.

Allocation to the “white” group was determined by an expert assessment of the patients' clinical condition and the results of laboratory tests:
1) Reduction in the clinical signs of pneumonia and the level of markers of the systemic inflammatory response
2) Clinical and laboratory signs of improved gas exchange
3) Positive dynamics according to computed tomography of the chest.
4) CPIS scale - 5 points or less on the 5th day of observation.

Determination of the plasma concentration of cytokines

To measure cytokine and chemokine concentrations in plasma we used Bio-Plex 27-plex and 37-plex kits (Bio-Rad, USA), measurements were performed using the Bio-Plex® MAGPIX™ multiplex analysis system (Bio-Rad, USA). A multiplex enzyme immunoassay of plasma samples was performed on Magpix magnetic particles (Bio-Rad, USA). We determined the concentrations of 59 cytokines: interleukin-1 receptor antagonist (IL-1ra), interleukin-1 beta, interleukin-2, interleukin-4, interleukin-5, interleukin-6 (IL-6), interleukin-7, interleukin-8, interleukin-9, interleukin -10, interleukin-12 (IL-12), interleukin-13, interleukin-15, interleukin-17, Interferon gamma-inducible protein-10, eotaxin, granulocyte colony stimulating factor (G-CSF), colony-stimulating factor of granulocytes and macrophages, interferon gamma, monocytic chemotactic protein-1, macrophage inflammatory protein 1-alpha, macrophage inflammatory protein 1-beta, basic fibroblast growth factor, platelet growth factor (PDGF-BB), vascular endothelial growth factor, chemokine expressed and secreted by T cells upon activation (RANTES), tumor necrosis factor alpha, a member of the tumor necrosis factor 13 ligand superfamily (APRIL or TNFSF13), B-lymphocyte activating factor (BAFF), cell membrane protein from the tumor necrosis factor receptor family (sCD30), soluble hemoglobin receptor expressed on the cell membrane of macrophages (sCD163), chitinase 3-like protein 1 (Chitinase 3-like), glycoprotein 130 (gp130 / sIL-6Rb), interferon alpha-2, interferon beta, interleukin-6 alpha receptor, interleukin-11, interleukin-12p40, interleukin-19, interleukin-20, interleukin-22, interleukin-26, interleukin-27p28, interleukin-28A (IL-28A / IFN-lambda2), interleukin-29 (IL-29 / IFN-lambda1), interleukin-32, interleukin-34, interleukin-35, protein of the tumor necrosis factor superfamily 14 (LIGHT or TNFSF14), matrix metalloproteinase 1, matrix metalloproteinase 2 (MMP-2), matrix metalloproteinase 3, osteocalcin, osteopontin, pentraxin-3, soluble tumor necrosis factor receptor 1, soluble tumor necrosis factor receptor 2, thymic stromal lymphopoietin (TSLP), weak inductor of apoptosis, associated with tumor necrosis factor (TWEAK).

Statistical data analysis

Statistical data processing was carried out using the PASW Statistics 22 program. The samples were examined for normality using the Shapiro-Wilks test. Descriptive statistics for quantitative variables are presented as mean, median, and 25th and 75th percentiles, outliers calculated from the exclusive median. To compare quantitative data in two unrelated samples, we used Student's t-test for parameters distributed normally, and Mann-Whitney U-test for parameters whose distribution was different from normal. The nonparametric Wilcoxon test was used to compare quantitative data in two related populations.
The significance level (p) was taken equal to 0.05 in all comparisons.

To assess the prognostic significance of the absolute value of cytokine concentrations and their changes within 3 days, ROC analysis (Receiver Operator Characteristic) was used. Indicators with high values of sensitivity / specificity and statistical significance were selected and thresholds for diagnostic criteria were determined. The overall predictive value of the markers was assessed by the area under the curve (AUC). The absolute values and changes in cytokine concentration were used to build a predictive model. The multivariate predictive model was constructed using the logistic regression method with stepwise elimination of variables according to Wald’s algorithm.

The study was approved by the Interuniversity Ethics Committee, Protocol No. 03-15 dated 03.19.2015.

### Results

#### Changes in cytokine concentrations with different responses to VAP therapy

We selected 73 patients who met the criteria for inclusion in the study. The demographic characteristics of the patients are presented in Table 1.

| Characteristic                        | All patients N = 73 | «White» group N = 36 | «Red» group N = 37 |
|--------------------------------------|--------------------|----------------------|---------------------|
| Age, years                           | 54.8 ± 17.2        | 55.8 ± 17.2          | 53.8 ± 17.3         |
| Sex                                  |                    |                      |                     |
| Men                                  | 55% (40)           | 61.1% (22)           | 48.6% (18)          |
| Women                                | 45% (33)           | 38.9% (14)           | 51.4% (19)          |
| Main diagnosis (damage or disease of the central nervous system) |                      |                      |                     |
| Hemorrhagic stroke                   | 21.9% (16)         | 22.2% (8)            | 21.6% (8)           |
| Ischemic stroke                      | 13.7% (10)         | 16.7% (6)            | 10.8% (4)           |
| Postresuscitation                    | 9.6% (7)           | 2.8% (1)             | 16.2% (6)           |
| Brain tumor                          | 19.2% (14)         | 19.4% (7)            | 18.9% (7)           |
| Brain arterial aneurysm              | 6.8% (5)           | 11.1% (4)            | 2.7% (1)            |
| Closed head injury                   | 15.1% (11)         | 8.3% (3)             | 21.6% (8)           |
| Open head injury                     | 6.8% (5)           | 8.3% (3)             | 5.4% (2)            |
| Others                               | 6.8% (5)           | 11.1% (4)            | 2.7% (1)            |

To assess changes in the immune status of patients with different responses to treatment, a comparison was made of cytokine concentrations on the 1st and 3rd days within the groups, as well as between groups on the 1st day of the study. The presence of objective differences in the clinical state of the patients between the “red” and “white” groups confirms the significantly different level of leukocytosis on the 1st day and significant differences in body temperature on the 3rd day. In terms of the absolute value of cytokine concentration on the 3rd day, statistically significant differences between the groups were not detected. On day 1, the plasma concentrations of IL-6, MMP-2 and sTNF-R2 significantly differed between the “red” and “white” groups (Mann-Whitney test, p < 0.05, Figure 1).

Further, the dynamics of cytokine concentration between the first and third days within each group was investigated. The Wilcoxon test of significant ranks (p < 0.05) revealed statistically significant differences. In the “white” group, on day 3, the concentrations of cytokines MMP-2, osteocalcin and TWEAK significantly increased and the concentrations of IL-1ra, IL-6, G-CSF, LIGHT, pentraxin, TSLP decreased (Figure 2).

In the “red” group, by day 3 the concentration of MMP-2 significantly decreased and the concentration of IL-12 increased (Figure 3).

Despite the presence of statistically significant dynamics in cytokine concentration, on average, the difference between the absolute values on the first and third days did not exceed 50 pg/ml. Due to the considerable scatter of data and small sample sizes, the change in the concentration of most cytokines did not differ significantly between the “red” and “white” groups. Only the dynamics
The prognostic value of changes in the plasma cytokine profile of neuroresuscitation patients

of MMP-2 concentration differed significantly between the groups (p <0.05, Mann-Whitney test). In the “white” group the average increase in the concentration of MMP-2 was 1265.25 pg/ml, in the “red” group the average decrease was -2118.90 pg/ml (Figure 4).

ROC analysis of significant predictors of favorable outcome

To assess the predictive value of the dynamics of cytokines, the concentration of which changed significantly,
The prognostic value of changes in the plasma cytokine profile of neuroresuscitation patients was assessed using ROC analysis. Sensitivity and specificity values at various cut-off points were used to construct ROC curves, the overall marker efficacy was assessed using the area under the curve (AUC). The results with confidence intervals (CI) are presented in Table 2.

MMP-2 has a significantly higher predictive power compared to other cytokines. AUC values below 0.7 indicate a low value of other cytokines as predictors of VAP outcome, therefore MMP-2 was chosen for further research. Figure 5 shows the ROC-curve of changes in the concentration of this cytokine as a criterion for the outcome of VAP. With the chosen threshold value of -659.0 picograms, the sensitivity and specificity were 82.1% and 70.8%, respectively.

**Table 2. AUC for significant predictors of clinical outcome.**

| Cytokine | AUC  | 95% CI lower | 95% CI upper | Significance |
|----------|------|--------------|--------------|--------------|
| IL-1RA   | 0.642| 0.510        | 0.775        | 0.038        |
| G-CSF    | 0.643| 0.515        | 0.772        | 0.037        |
| IL-10    | 0.677| 0.526        | 0.828        | 0.029        |
| LIGHT    | 0.686| 0.534        | 0.838        | 0.022        |
| MMP-2    | 0.768| 0.636        | 0.900        | 0.001        |
| TWEAK    | 0.680| 0.530        | 0.830        | 0.026        |

**Prognostic model**

In order to further study the predictive markers of the clinical course of VAP, we built a predictive model based on the logistic regression method. Using stepwise inclusion of variables, cytokines that did not increase prediction accuracy were eliminated. The model was built on the basis of changes in the concentration of MMP-2. Based on the constructed model, it can be concluded that the dynamics of MMP-2 can be a predictor of allocation into the “white” or “red” group with an accuracy of 69.2% (p = 0.013).
Among all cytokines, according to the results using classical methods of statistics, ROC-analysis and the logistic regression model, the concentration of MMP-2 turned out to be the most sensitive predictor of the clinical course of VAP. An increase in MMP-2 concentration can predict or indicate a favorable course of VAP and successful antibiotic therapy, a decrease - a high risk of an unfavorable clinical course.

**Discussion**

Literature data indicate a relationship between the patient's immune status and the clinical course of VAP [10,11]. The clinical response to treatment is largely determined by the interaction between the pathogen and components of the immune system. The activity of one or another component of the immune system is manifested by the release of cytokines necessary for the recruitment and phenotyping of certain leukocytes. Since the lung tissue is abundantly supplied with blood, an increase in the concentration of cytokines can be expected when they are released in the focus of inflammation [12]. We investigated a wide range of cytokines by enzyme immunoassay on the first and third days after the start of patient observation. Of the 59 investigated cytokines, only a few had a significantly different concentration between the groups or between the 1st and 3rd days. It can be assumed that the production of most cytokines is stable regardless of the course of the disease, or that their release in the inflammation focus does not cause a transfer into the bloodstream.

The most promising cytokine, according to the results of this study, turned out to be matrix metalloproteinase-2, the main substrates of which are type 4 collagen and elastin - components of the basal lamina. MMP-2 is involved in tissue remodeling and modulation of inflammation. Studies have shown changes in the plasma concentration of MMP-2 in severe sepsis, reflecting the degree of organ dysfunction [13, 14]. We did not find literature data on the value of MMP-2 as a marker of the effectiveness of antibiotic therapy and the severity of the clinical course of VAP. J-S. Hong et al., in an experimental study, showed that matrix metalloproteinases 2 and 9 are necessary for an adequate immune response in pneumonia caused by a typical pathogen *Streptococcus pneumoniae*. The production of MMP-2 is important for the phagocytosis of bacteria by macrophages and the release of active forms of oxygen by neutrophils [15]. I. Puljiz et al. studied the concentration of MMP-2 in community-acquired pneumonia caused by Mycoplasma pneumoniae. The authors found that the plasma levels of MMP-2 in patients with community-acquired pneumonia is higher at the convalescence stage and lower in the acute phase of the disease, compared to patients in the control group [16]. A study by H. Bircan et al. showed that the concentration of MMP-2 was higher in patients with community-acquired pneumonia and correlated with a worse prognosis of treatment [17]. This is fully consistent with the results obtained in our study: the concentration of MMP-2 was significantly higher on the 1st day in the high-risk (“red”) group compared with the low-risk (“white”) group, but on the 3rd day it significantly decreased. Based on the logistic regression method, we built a predictive model to assess the predictive ability of MMP-2 dynamics as a marker for determining the clinical response to therapy. With an accuracy of about 70%, the dynamics of MMP-2 made it possible to predict a favorable or unfavorable clinical course of the disease. The significance of MMP-2 was also confirmed by classical statistical tests and ROC analysis. MMP-2 has an ambivalent role as a necessary component of the immune response and an effector of autodamage [18]. The results obtained confirm that both a high initial concentration of MMP-2 and its decrease in dynamics indicate a severe course of pneumonia. Based on the data obtained, it can be assumed that MMP-2 can serve as a marker of the effectiveness of antibiotic therapy in VAP, however, to clarify the results, further studies and larger group sizes are required.

A number of cytokines turned out to be weak predictors of the severity of the course of VAP, but statistically significant differences between their concentrations in the “white” and “red” groups on the 1st and 3rd days of observation indicate the prospects for further study on a larger group of patients. Baseline concentrations of (IL-6) and soluble TNFR-2 receptor were significantly higher in the red group than in the white group. While IL-6 has an ambivalent effect, and various authors refer to it as both a pro and anti-inflammatory cytokine, sTNFR-2
has a pronounced anti-inflammatory effect [19, 20]. It is possible that an increase in the concentration of these cytokines may be associated with the immunosuppressive effect of pathogens in severe pneumonia. In the “white” group on the 3rd day, the concentrations of osteocalcin and TWEAK significantly increased and the concentrations of IL-1RA, IL-6, G-CSF, LIGHT, TSLP decreased. A decrease in the concentration of all cytokines, with the exception of IL-1RA, directly indicates a lesser severity of the inflammatory response, which may be directly related to the milder clinical course of VAP [21–25]. IL-1RA is an anti-inflammatory cytokine; a decrease in its plasma concentration can be a consequence of both excessive autoagression of the immune system and a normal manifestation of the immune response [26]. Changes in the plasma concentrations of these cytokines in VAP require further study.

The lack of a significant differences between the absolute dynamics of parameters in the “white” and “red” groups can be explained by insufficient sample size. Further studies are required to investigate the predictive value of these cytokines as markers of the effectiveness of antibiotic therapy in VAP. In addition, it seems advisable to study the cytokine profile of patients when prescribing different broad-spectrum antibiotics.

**Conclusion**

The study of the plasma cytokine profile revealed statistically significant differences in the absolute dynamics of MMP-2 concentration in patients with a favorable and unfavorable clinical course of VAP. In the favorable course group, the average concentration increased significantly, while in the group with an unfavorable course of VAP, the plasma concentration of MMP-2 significantly decreased on the 3rd day of antibiotic therapy.

In addition to MMP-2, we obtained data on dynamic changes in the concentration of a number of other cytokines, which may be of interest for further study and require a larger sample size: IL-1ra, IL-6, G-CSF, LIGHT, osteocalcin, pentraxin, TSLP , TWEAK and IL-12.

The obtained results indicate the prognostic value of measuring the plasma concentrations of pro- and anti-inflammatory cytokines in the treatment of VAP.

**Disclosure.** The authors declare that they have no competing interests.

**Author contribution.** Zinya E.P., Tsarenko S.V., Logunov D.Y., Tukhvatulin A.I., Magomedov M.A., Babayants A.V., Avramov A.A. - all authors according to the ICMJE criteria participated in the development of the concept of the article, obtaining and analyzing factual data, writing and editing the text of the article, checking and approving the text of the article.

**Authors’ ORCID**

| Author | ORCID |
|--------|-------|
| Zinya E.P. | 0000-0002-3257-6034 |
| Tsarenko S.V. | 0000-0002-7065-5331 |
| Logunov D.Y. | 0000-0003-4035-6581 |
| Tukhvatulin A.I. | 0000-0001-8506-2339 |
| Magomedov M.A. | 0000-0002-1972-7336 |
| Babayants A.V. | 0000-0003-3072-3237 |
| Avramov A.A. | 0000-0001-6055-3289 |

**References**

[1] Нозокомиальная пневмония у взрослых: Российские национальные рекомендации / под ред. Б.Р. Гельфанд. 2-е изд. М.: ООО «Изд-во «Медицинское информационное агентство», 2016. [Nosocomial pneumonia of adults: Russian national guidelines / Main editor B.R. Gelfand; 2nd ed. Moscow: Medical information agency, 2016. (In Russ)]

[2] Leone M., Bouadma L., Bouhemad B., et al. Hospital-acquired pneumonia in ICU. Anaesth Crit Care Pain Med. 2018;37(1):83-98. DOI:10.1016/j.accpm.2017.11.006

[3] Гельфанд Б.Р., Белоцерковский Б.З., Милюкова И.А., и др. Эпидемиология и нозологическая структура нозокomialьных инфекций в отделении реанимации и интенсивной терапии многопрофильного стационара. Инфекции в хирургии. 2014; 4: 24-36. [Gelfand B.R., Belotserkovskiy B.Z., Milukova I.A., et al. Epidemiology and nosological structure of nosocomial infections in intensive care unit of multitype hospital. Surgical infections. 2014; 4: 24-36 (In Russ)]

[4] Iregoі, W., Ward S., Sherman G., et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122(1):262-268. DOI:10.1378/chest.122.1.262

[5] Ewig S., Torres A., El-Ebiary M., et al. Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury: Incidence, risk factors, and association with ventilator-associated pneumonia. Am J Respir Crit Care Med. 1999;159(1):188-198. DOI:10.1164/ajrccm.159.1.9803097

[6] Lord A.S., Nicholson J., Lewis A. Infection prevention in the neurointensive care unit: a systematic review. Neurocrit Care. 2019;31(1):196-210. DOI:10.1007/s12028-018-0568-y

[7] Lee H.S., Moon J., Shin H.R., et al. Pneumonia in hospitalized neurologic patients: Trends in pathogen distribution and antibiotic susceptibility. Antimicrob Res Infect Control. 2019;8(1). DOI:10.1186/s13756-019-0475-9

[8] Lorenzo M.-J., Moret I., Sarria B., et al. Lung inflammatory pattern and antibiotic treatment in pneumonia. Respir Res. 2015;16(1):15. DOI:10.1186/s12931-015-0165-y

[9] Torres A., Niederman M.S., Chastre J., et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-
The prognostic value of changes in the plasma cytokine profile of neuroresuscitation patients

[10] Mizgerd J.P. Inflammation and pneumonia: why are some more susceptible than others? Clin Chest Med. 2018;39(4):669-676. DOI:10.1016/j.ccm.2018.07.002

[11] Malyarchikov A.V., Shapovalov K.G., Lukyanov S.A., et al. Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Influenza A (H1N1). General Reanimatology. 2021;17(4):4-11. [In Russ]

[12] Karakioulaki M., Stolt D. Biomarkers in pneumonia—beyond procalcitonin. Int J Mol Sci. 2019;20(8). DOI:10.3390/ijms20082004

[13] Mühl D., Nagy B., Woth C., et al. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis. J Crit Care. 2011;26(6):550-555. DOI:10.1016/j.jcrc.2011.02.011

[14] Dal-Pizzol F., Rojas H.A., Dos Santos E.M., et al. Matrix metalloproteinase-2 and metalloproteinase-9 activities are associated with blood-brain barrier dysfunction in an animal model of severe sepsis. Mol Neurobiol. 2013;48(1):62-70. DOI:10.1007/s12035-013-8433-7

[15] Hong J.-S., Greenlee K.J., Pitchumani R., et al. Dual protective mechanisms of matrix metalloproteinases 2 and 9 in immune defense against Streptococcus pneumoniae. J Immunol. 2011;186(11):6427-6436. DOI:10.4049/jimmunol.1003449

[16] Puljiz I., Markotic A., Cvetko Krajnovic L., et al. Mycoplasma pneumoniae in adult community-acquired pneumonia increases matrix metalloproteinase-9 serum level and induces its gene expression in peripheral blood mononuclear cells. Med Sci Monit. 2012;18(8):CR500-505. DOI:10.12659/MSM.883270

[17] Bircan H.A., Cakir M., Yilmazer Kapulu I., et al. Elevated serum matrix metalloproteinase-2 and -9 and their correlations with severity of disease in patients with community-acquired pneumonia. Turkish J Med Sci. 2015;45(3):593-599. DOI:10.3906/sag-1402-51

[18] Fligiel S.E.G., Standford T., Fligiel H.M., et al. Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury. Hum Pathol. 2006;37(4):422-430. DOI:10.1016/j.humpath.2005.11.023

[19] Luig M., Kluger M.A., Goerke B., et al. Inflammation-Induced IL-6 Functions as a Natural Brake on Macrophages and Limits GN. J Am Soc Nephrol. 2015;26(7):1597-1607. DOI:10.1681ASN.2014060620

[20] Petelin M., Narushi K., Shiami N., et al. Systemic up-regulation of sTNFR2 and IL-6 in Porphyromonas gingivalis pneumonia in mice. Exp Mol Pathol. 2004;76(1):76-81. DOI:10.1016/j.xympp.2003.09.002

[21] Hashiguchi M., Kashiwakura Y., Kanno Y., et al. Tumor necrosis factor superfamily member (TNFSF) 13 (APRIL) and TNFSF13B (BAFF) downregulate homeostatic immunoglobulin production in the intestines. Cell Immunol. 2018;323:41-48. DOI:10.1016/j.cellimm.2017.10.009

[22] Ziegler S.F., Roan F., Bell B.D., et al. The biology of thymic stromal lymphopoietin (TSLP). Adv Pharmacol. 2013;66:129-155. DOI:10.1016/S978-0-12-404717-4.00004-4

[23] Barkhausen T., Tschernig T., Rosenstiel P., et al. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med. 2011;39(6):1407-1413. DOI:10.1097/CCM.0b013e318211ff56

[24] Liao M., Huang L., Mao Y., et al. Serum Osteocalcin Is Associated With Inflammatory Factors in Metabolic Syndrome: A Population-Based Study in Chinese Males. Mediators Inflamm. 2015;2015:683739. DOI:10.1155/2015/683739

[25] Ishikawa H., Fukui T., Ino S., et al. Influenza virus infection causes neutrophil dysfunction through reduced G-CSF production and an increased risk of secondary bacteria infection in the lung. Virology. 2016;499:23-29. DOI:10.1016/j.virol.2016.08.025

[26] Awasthi S., Yadav K.K., Pandey M., et al. Interleukin 1 receptor antagonist (IL1RA) gene polymorphism and levels associated with adverse outcome in severe community-acquired pneumonia in children: A hospital-based study in India. Pediatr Pulmonol. 2018;53(9):1276-1283. DOI:10.1002/ppul.24090

[27] Schurink C.A.M., Nieuwenhoven C.A.V., Jacobs J.A., et al. Clinical pulmonary infection score for ventilator-associated pneumonia: accuracy and inter-observer variability. Intensive Care Med. 2004;30(2):217-224. DOI:10.1007/s00134-003-2018-2.

[28] Radivyllov A.S., Grigor’ev E.V., Shuknevich D.L., Plotnikov G.P. Прогнозирование и ранняя диагностика полиорганной недостаточности. Анестезиология и реаниматология. 2004;30(2):217-224.

[29] Radivyllov A.S., Grigor’ev E.V., Shuknevich D.L., Plotnikov G.P. Prognostization and early diagnosis of polyorgan failure. Russian Journal of Anaesthesiology and Reanimatology. 2004;30(2):217-224. DOI:10.1016/j.anesthesia.2004.03-2018-2.

[30] Zinina E.P., Tsarenko S.V., Logunov D.Y., et al. The role of proinflammatory and anti-inflammatory cytokines in bacterial pneumonia. Review. Annals of Critical Care. 2021;1:77-89. (In Russ)

[31] Zinina E.P., Tsarenko S.V., Logunov D.Y., et al. The role of proinflammatory and anti-inflammatory cytokines in bacterial pneumonia. Review. Annals of Critical Care. 2021;1:77-89. (In Russ) DOI: 10.21320/1818-474X-2021-1-77-89
